Background: Immune checkpoint inhibitors (ICIs) are a new class of therapy for patients with non-small cell lung cancer (NSCLC). Immunologic markers, such as serum neutrophil-to-lymphocyte ratio (NLR), are prognostic in patients with a variety of malignancies, with preliminary findings in patients on immunotherapy. In this study, we evaluate the association between NLR and ICI outcomes in NSCLC, including the development of immune-related adverse events (irAEs). Method: We conducted a retrospective analysis of advanced or recurrent NSCLC patients receiving ICI from 2011 to 2017. Demographics, disease and treatment history, and pretreatment labs were recorded. An NLR 3 5 was defined as high and <5 as low, based on metaanalyses. Cox proportional hazards models and univariate and multivariate regressions were used to assess the association between NLR
Background: Blood-based cell-free tumor DNA (ctDNA) could be dynamically monitored to provide gene alterations during EGFR-TKI treatment, which might offer critical clue for prognosis and clinical treatment decision. Here we reported the dynamic gene alterations monitoring using next generation sequencing (NGS) in BENEFIT study to explore the mechanisms of different responses and resistances to EGFR-TKI in EGFR-sensitizing-mutated lung-adenocarcinoma (LADC) patients. Method: Patients with systemic treatment-naïve, stage IV LADC and EGFR-sensitizing-mutation in ctDNA were enrolled to receive gefitinib. Blood samples were dynamically obtained at baseline, every 8 weeks and at disease progression (PD). The dynamic analysis of quantity of ctDNA, multiple driver genes and tumor suppressors were investigated with NGS (Nextseq500 sequencer, consisting of critical exons/introns of 168 genes), and were correlated with efficacy and resistance. Result: Totally 181 LADC patients with EGFR-sensitizing-mutation (exon-19-deletion and exon-21-L858R-point-mutation) provided sufficient blood samples for NGS analysis at baseline, of which 143 patients obtained at least four timepoints of dynamic blood sample collection until PD (baseline, 8 weeks, 8 weeks before PD and PD). At baseline, 180 of patients (99.4%) were confirmed as EGFR-sensitizing-mutation with NGS (92 EGFR-19-deletion and 88 EGFR-L858R-point-mutation) including 44 (24.3%) EGFR-amplification, 116 (64%) TP53-mutation, or other known oncogenic drivers including MET (N¼5, 2.8%), ERBB2 (N¼7,3.9%), KRAS (N¼6, 3.3%), BRAF (N¼2, 1.2%), RET (N¼1, 0.6%), ROS1 (N¼1, 0.6%), or EGFR-T790M (N¼4, 2.2%), which was correlated with poor efficacy compared with those with only EGFR-sensitizing-mutation (PFS 4.7 months [m] vs. 13.2m , p¼0.002). Additionally, tumor suppressor genes exhibiting cumulative effect to poor prognosis: PFS for 164 patients with TP53andRB1andPTEN-muta-tion1 was 11.1m, while for 16 patients with TP53andRB1andPTEN-mu-tation＞1，PFS was 4.7 m, p<0.0001. To cut-off date, 117 patients had PD, among them, 63 (54%) patients acquired EGFR-T790M-mutation presented as dominant resistance mechanism besides MET-amplification/ERBB2amplification/ERBB2-S310F (N¼16, 14%), RET fusion/splice (N¼2, 1.7%), ROS1-C2336F-mutation (N¼1, 0.9%), RB1-nonsense-mutation (N¼2, 1.7%), TP53-Y205S-mutation (N¼1, 0.9%) and TP53-Y205S-mutation accompanied with FGFR1-amplification (N¼1, 0.9%). The remaining resistance mechanisms (31%) were unknown. Patients with only T790M-mutation had a significantly longer PFS (11.5m) compared with patients obtaining other acquired resistant mechanisms (3.0m). Interestingly, seventy-five (53.2%) patients had molecular progression before radiographic progression, and the median time difference was 8.7 weeks. Conclusion: Dynamic alterations of multi-drivers and suppressors together with EGFR-sensitizing-mutation and T790M-mutation could separate LADC into different subgroups with distinguished molecular features, which may play a vital role during EGFR-TKI treatment for resistance-predicting, and initial/subsequent treatment decision-making. Keywords: multi-drivers, ctDNA, EGFR mutation P2.01-102 Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients Z. Wang, 1 D. Zhu, 2 B. Lu, 1 G. Liu, 1 T. Xu 1 1 Cancer Medical Center, the Second Affiliated Hospital of Nanjing Medical University, Nanjing/CN, 2 Nanjing Geneseeq Technology Inc., Nanjing/CN Background: Next-generation sequencing (NGS) has been increasingly involved in the clinical decision-making of cancer care, the primary applications of which are the identification of sensitizing mutations for targeted therapies and drug-resistant mechanisms. Along with more clinical validations and approvals of several commercially available targeted NGS panels by FDA for mutation profiling, it has been debated that whether comprehensive NGS test should be used as a standard procedure in clinical practice. Method: In this study, we recruited 24 patients with stage IV lung cancer. 22 of them are adenocarcinoma and the other 2 are small cell lung cancer and squamous cell carcinoma, respectively. Genomic DNA from 13 tumor tissues, and circulating tumor DNA from 8 pleural effusions and 3 plasma samples in each corresponding patient were collected and subjected to targeted-NGS covering 416 cancer-related genes and 16 genes frequently rearranged in solid tumors. Targeted therapy or chemo/ radiochemotherapy was applied in clinical practice with the consideration of patients' requests and their affordability due to financial barriers. Patients' clinical outcomes were further evaluated. Result: Of all patients, 54% of them (n¼13) were detected with sensitizing mutations that have targeted drugs available, including EGFR exon 19 deletion (n¼2), L858R (n¼2) and L861Q mutations (n¼1), ALK fusion (n¼1), ROS1 fusion (n¼1), MET exon 14 skipping (n¼1), as well as EGFR T790M (n[5) for 4 patients who had progressed on the first-generation tyrosine kinase inhibitors (1 st -gen TKI) and 1 TKI-treatment naive patient. 69% of patients (n¼9) with actionable mutations were subjected to targeted treatment, while the other 31% patients (n ¼ 4) were treated with chemotherapy or radiochemotherapy. Consistent with clinical validations, the overall survival (OS) of targeted-treatment group is better than the systematic treatment group. On the other hand, for patients without detectable actionable mutations (n¼11), 64% of patients (n¼7) were underwent chemotherapy, while the rest were treated with 1 st -gen EGFR TKI as requested by the patients. As expected, chemotherapy-treatment group had a similar OS as the TKI group. Collectively, patients with sensitizing mutations achieved significantly longer OS from the TKI treatments than those without actionable mutations (p¼0.02). Conclusion: Our data demonstrated that the existence of sensitizing mutation is the determining factor for the treatment efficacy of targeted therapies. In the real world, NGS test can not only be involved into the decision-making for the first line treatment, but also be instructive for treatment changes after drugresistance developed Keywords: lung cancer, targeted treatment, nextgeneration sequencing P2.01-103 Neutrophil-to-Lymphocyte Ratio as a Predictor of Immunotherapy Treatment Outcomes in Advanced Non-Small Lung Cancer and overall survival (OS), progression-free survival (PFS), disease control rate at 10 weeks (DCR), and irAEs. Result: 183 patients were identified: 55.2% male, 76.5% Caucasian, mean age 65.3 years (range 38e90 years). Male sex, smoking history, prior radiotherapy, and pretreatment albumin were significantly associated with high versus low NLR (p < 0.05). In univariate analyses, pretreatment NLR was a significant predictor of OS (HR 1.47, p < 0.05, Fig. 1 ), PFS (HR 1.44, p < 0.05), and DCR (OR 0.49, p < 0.05), but not irAEs (OR 1.37, p ¼ 0.33). These findings persisted with multivariate analyses (OS HR 1.76, PFS HR 1.64, DCR OR 0.24, all p < 0.01; irAE OR 1.52, p ¼ 0.33). Conclusion: High NLR was positively associated with OS, PFS, and DCR but not irAEs in NSCLC patients receiving ICI. Our results support the use of NLR as a biomarker for clinical outcomes. Prospective studies are needed to study this measure in patients undergoing ICI therapy, and further studies to identify predictive biomarkers of irAEs are warranted. Keywords: Prognostic factors, Immunotherapy, advanced NSCLC
P2.01-104
Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value B. Weerasubpong, 1 C. Vinayanuwattikun, 1 P. Chantranuwatana, 2 V. Sriuranpong 1 1 Faculty of Medicine Chulalongkorn University, Bangkok/TH, 2 Pathology, Chulalongkorn University, Bangkok/TH Background: Non-tumor derived circulating DNA (nt-cirDNA) of advanced non-small cell lung cancer (NSCLC) patient, even not yet clear originated, was associated with prognosis. In this study, we investigated whether T-cell-derived circulating DNA (T-cirDNA) was the majority part of nt-cirDNA nor correlated with tumor-infiltrating Tlymphocyte (T-TIL). Method: Prognostic impact including demographic characteristics were integrated into the model. Using Quantitative realtime PCR with Taqman assay specific to VDJ segment of TCR b (T-cellreceptor beta chain) was used to represented amount of T-cirDNA in plasma of 106 advanced stage NSCLC. Quantitative CD3-specific immunohistochemistry (IHC) staining from biopsy specimen, represented T-TIL, was done using Aperio ImageScope. Result: T-cirDNA was detected in seventy-three advanced NSCLC patients with a median of 1.71 pg/ml [range 0-2260]. Forty-six patients were assessed for proportion of T-TIL per total cell with a median of 0.22 per mm 2 [range 0.02-2.34]. No correlation was found between T-cirDNA and T-TIL. From multivariable analysis, active smoking status was the only factor correlated with low T-cirDNA level (P<0.001). Kaplan Meier survival analysis of T-cirDNA ratio (T-cirDNA/total cirDNA) shown a trend of favor prognostic outcome for high T-cirDNA ratio (more than 0.03 %), HR 0.67 [95% CI 0.43-1.04, P¼0.07]. Conclusion: plasma T-cirDNA component, even not correlated with T-TIL, revealed a trend of prognostic impact in advanced stage non-small-cell cancer patients. Background: Tumor Treating Fields (TTFields) is a non-invasive, antimitotic treatment approved for glioblastoma based on significant survival outcomes in a Phase 3 trial. Efficacy of TTFields in NSCLC has been shown preclinically and the safety confirmed in a phase I/II pilot study combined with pemetrexed. In the LUNAR study [NCT02973789], we investigated if adding TTFields to immune checkpoint inhibitors or docetaxel following platinum doublet failure will increase overall survival. Method: s: Patients (N¼534), with squamous or non-squamous NSCLC, are stratified per selected standard therapy (immune checkpoint inhibitors or docetaxel), histology (squamous vs. non-squamous) and geographical region. Key inclusion criteria: disease progression while on/after platinum-based therapy, ECOG 0-2, no electronic medical devices in the upper torso, and absence of brain metastasis. Docetaxel or immune checkpoint inhibitors are given at standard doses. TTFields are applied to the upper torso for >18 hours/day, allowing patients to maintain daily activities. TTFields are continued until progression in the thorax and/or liver. Follow-up is performed once q6 weeks using CT scans of the chest and abdomen. On progression in the thorax and/or liver, patients have 3 post-progression follow-up visits and are then followed monthly for survival. The primary endpoint is superiority in OS with TTFields in combination with the standard of care treatments versus (vs) standard of care treatments alone. Key secondary endpoints compare the OS in patients treated with TTFields and docetaxel vs docetaxel alone, and patients treated with TTFields and immune checkpoint inhibitors vs those treated with immune checkpoint inhibitors alone. An exploratory analysis will test non-inferiority of TTFields with docetaxel compared to checkpoint inhibitors alone. Secondary endpoints include progression-free survival, radiological response rate, quality of life based on the EORTC QLQ C30 questionnaire and severity and frequency of adverse events. The sample size is powered to detect a HR of 0.75 in TTFields-treated patients versus control group. Result: Section not applicable Conclusion: Section not applicable Keywords: Tumor Treating Fields; stage 4 non-small cell lung cancer; platinum failure
